DOCSLIB.ORG

Starting on SPRYCEL® (Dasatinib) TABLE of CONTENTS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Starting on SPRYCEL® (Dasatinib) TABLE of CONTENTS Starting on SPRYCEL® (dasatinib) TABLE OF CONTENTS 2 4 13-18 28 YOU’VE BEEN DIAGNOSED... TALK TO YOUR DOCTOR PATIENT-TO-PATIENT ABOUT... RESOURCES 7 20-23 31 WHAT CAUSES IT? TAKING SPRYCEL® (dasatinib) ADDITIONAL SOURCES FOR INFORMATION AND SUPPORT 9 24-26 A NEW DIRECTION INDICATIONS AND IMPORTANT SAFETY INFORMATION 10 THE GOALS INDICATIONS AND USAGE SPRYCEL® (dasatinib) is a prescription medicine used to treat adults who have: SELECT IMPORTANT • Newly diagnosed Philadelphia SAFETY INFORMATION chromosome-positive (Ph+) chronic myeloid leukemia SPRYCEL may cause serious side (CML) in chronic phase. The effects, including low blood cell effectiveness of SPRYCEL in counts, bleeding, fluid retention, these patients is based on heart problems, and pulmonary 3 a study that measured two arterial hypertension. Other types of response to treatment common side effects of SPRYCEL (cytogenetic and molecular) by include diarrhea, headache, 1 year. The study is ongoing to cough, skin rash, fever, nausea, find out how SPRYCEL works tiredness, vomiting, muscle pain, over a longer period of time weakness, and infections. This • Ph+ CML who are no longer is not a complete list of all side benefitting from, or did not effects recorded in clinical studies tolerate, other treatment with SPRYCEL. Tell your healthcare including Gleevec® provider if you have any side effects (imatinib mesylate) while taking SPRYCEL. Please read pages 16-18 for additional Important Safety Information about SPRYCEL. Please read the Patient Information section of the full Prescribing Information on pages 30-31. YOU’VE BEEN DIAGNOSED WITH But it’s important to know that PHILADELPHIA with the treatments available Your doctor is your ongoing today, many people with partner in treatment. Being open CHROMOSOME- Ph+ CML may be able to about what you’re feeling, and POSITIVE (Ph+) continue living productive and asking any questions you may satisfying lives. CHRONIC have are important parts of the partnership. 4 MYELOID Know that you’re LEUKEMIA not alone And don’t forget about (CML)... You probably have many questions friends and loved ones about the disease and your The news that you have Ph+ CML treatment. The goal of this kit is It’s up to you to decide who you has probably come as a shock to help answer some of those want to talk to about your condition. to you and your loved ones. And questions. And when. But you may find that, you may find yourself feeling sad, given the chance, friends and loved depressed, or afraid. These are very Your healthcare team is the best ones may provide their own very normal reactions. resource for information. special kind of care. About 70,000 people in America are living with Ph+ CML. And around 6,000 people are newly diagnosed each year. What is Philadelphia chromosome-positive causes the bone marrow to produce more white blood cells, (Ph+) chronic myeloid even when they are not needed. CML: LET’S leukemia (CML) in These are mostly damaged chronic phase? or immature. Over time, these START extra, unhealthy white blood 5 FROM THE It’s a mouthful, that’s for sure. cells overcrowd healthy white So let’s try to break it down: blood cells, red blood cells, and BEGINNING platelets. 1. Ph+ CML, or chronic myeloid What is leukemia? leukemia, is a type of leukemia. 3. The lack of healthy blood cells It is caused by an abnormal and platelets leads to the signs Leukemia is a kind of blood chromosome in the body and symptoms of Ph+ CML. cancer that begins in the bone called the Philadelphia (or Ph) marrow. That is the soft tissue chromosome. 4. Usually, when people are in the center of your bones that diagnosed with Ph+ CML, they produces all types of blood 2. The Ph chromosome creates are in the “chronic phase.” CML cells. There are different forms what is known as the BCR-ABL symptoms are milder in the of leukemia. The kind you have is cancer gene. When you have chronic phase, compared to called Ph+ CML. Ph+ CML, the BCR-ABL protein later phases. Please read pages 16-18 for additional Important Safety Information about SPRYCEL. Please read the Patient Information section of the full Prescribing Information on pages 30-31. SPRYCEL (dasatinib) has been prescribed for over 8 years IMPORTANT SAFETY INFORMATION since initial FDA approval, with It is not known if more than 220,000 TKIS: A NEW SPRYCEL® (dasatinib) is safe and effective in children prescriptions DIRECTION IN younger than 18 years old. TREATMENT written. Before you take SPRYCEL, tell Not too long ago, people with your healthcare provider if you: 6 Ph+ CML were given traditional • have problems with your treatments such as chemotherapy. immune system Then a whole new kind of therapy • have liver problems was developed, giving patients more • have heart problems healthcare provider right away treatment options. This new therapy • are lactose intolerant if you are pregnant or plan to is called tyrosine kinase inhibitors • have any other medical become pregnant (TKIs). conditions • are breast-feeding or plan to • are pregnant or planning to breast-feed. It is not known Once people with chronic phase become pregnant. SPRYCEL if SPRYCEL passes into your Ph+ CML start treatment, they can harm your unborn baby. breast milk or if it can harm your may feel well enough to continue Sexually active female patients baby. You and your healthcare their day-to-day activities such of childbearing potential provider should decide if you will as working, spending time with taking SPRYCEL should take SPRYCEL or breast-feed. family, running errands, etc. avoid pregnancy. Talk to your You should not do both Please read pages 16-18 for additional Important Safety Information about SPRYCEL. Please read the Patient Information section of the full Prescribing Information on pages 30-31. IMPORTANT SAFETY It’s important to THE GOALS OF INFORMATION ABOUT LOW remember that 7 TREATMENT BLOOD CELL COUNTS CML is a chronic WITH ® SPRYCEL (dasatinib) may cause disease. Do your SPRYCEL low red blood cell counts (anemia), part and take your low white blood cell counts (dasatinib) (neutropenia), and low platelet medication daily, counts (thrombocytopenia). as prescribed by The immediate goal of treatment is Your healthcare provider will do your doctor. to reduce any symptoms of CML blood tests to check your blood you may have. The longer-term goal cell counts regularly during your is to decrease cancer cells to a level treatment with SPRYCEL. Call your that is not detectable by testing. healthcare provider right away if This may slow down the disease you have a fever or any signs of an from progressing. infection while taking SPRYCEL. Please read pages 16-18 for additional Important Safety Information about SPRYCEL. Please read the Patient Information section of the full Prescribing Information on pages 30-31. TALK TO YOUR You may find it helpful to keep a 8 HEALTHCARE pen and paper or journal nearby TEAM ABOUT so that you can make note of any Talk to your doctor SIDE EFFECTS side effect you might feel. right away if you This is also a great way to keep have any side Your doctor and your healthcare track of any questions that come effects. Don’t wait team need to know about any side to your mind. By writing these for your symptoms effect of treatment that bothers you things down, you’ll be able to have or that does not go away. No matter everything you need handy when to get worse! how small the change may seem, you speak with your doctor or other they will want to know about it. member of your healthcare team. Please read pages 16-18 for Important Safety Information about SPRYCEL. Please read the Patient Information section of the full Prescribing Information on pages 30-31. SIDE EFFECTS Call your healthcare provider This kind of bleeding is also ® OF SPRYCEL right away if you have a fever or known as thrombocytopenia. any signs of an infection while (dasatinib) taking SPRYCEL. If your doctor suspects you have bleeding, he or she will probably Here are some side effects of Low blood cell counts are also do a physical exam and blood tests. SPRYCEL® (dasatinib) that you known as myelosuppression. should be aware of. It is not a Fluid retention complete list of all side effects Bleeding recorded in clinical studies. SPRYCEL may cause your body to SPRYCEL may cause severe hold too much fluid. In severe cases, Low blood cell counts bleeding that can lead to death. fluid may build up in the lining of your lungs, the sac around your heart, or 9 Call your healthcare provider your stomach cavity. SPRYCEL may cause low red blood right away if you have: cell counts (anemia), low white blood • unusual bleeding or bruising Call your healthcare provider cell counts (neutropenia), and low of your skin right away if you get any of these platelet counts (thrombocytopenia). • bright red or dark, symptoms during treatment with Your healthcare provider will do tar-like stools SPRYCEL: blood tests to check your blood • a decrease in your level of • swelling all over your body cell counts regularly during your consciousness, headache, • weight gain treatment with SPRYCEL. or change in speech • shortness of breath and cough (continued on next page) Please read pages 16-18 for additional Important Safety Information about SPRYCEL. Please read the Patient Information section of the full Prescribing Information on pages 30-31. Talk to your doctor right away if you have any side effects. Don’t wait for your symptoms SIDE EFFECTS to get worse! OF SPRYCEL® (dasatinib) cont’d Fluid retention in your lungs is 10 also known as pleural effusion.
Load more

Recommended publications
  • Management of Chronic Myelogenous Leukemia in Pregnancy
    ANTICANCER RESEARCH 35: 1-12 (2015) Review Management of Chronic Myelogenous Leukemia in Pregnancy AMIT BHANDARI, KATRINA ROLEN and BINAY KUMAR SHAH Cancer Center and Blood Institute, St. Joseph Regional Medical Center, Lewiston, ID, U.S.A. Abstract. Discovery of tyrosine kinase inhibitors has led to Leukemia in pregnancy is a rare condition, with an annual improvement in survival of chronic myelogenous leukemia incidence of 1-2/100,000 pregnancies (8). Since the first (CML) patients. Many young CML patients encounter administration of imatinib (the first of the TKIs) to patients pregnancy during their lifetime. Tyrosine kinase inhibitors with CML in June 1998, it is estimated that there have now inhibit several proteins that are known to have important been 250,000 patient years of exposure to the drug (mostly functions in gonadal development, implantation and fetal in patients with CML) (9). TKIs not only target BCR-ABL development, thus increasing the risk of embryo toxicities. tyrosine kinase but also c-kit, platelet derived growth factors Studies have shown imatinib to be embryotoxic in animals with receptors α and β (PDGFR-α/β), ARG and c-FMS (10). varying effects in fertility. Since pregnancy is rare in CML, Several of these proteins are known to have functions that there are no randomized controlled trials to address the may be important in gonadal development, implantation and optimal management of this condition. However, there are fetal development (11-15). Despite this fact, there is still only several case reports and case series on CML in pregnancy. At limited information on the effects of imatinib on fertility the present time, there is no consensus on how to manage and/or pregnancy.
    [Show full text]
  • The Effects of Combination Treatments on Drug Resistance in Chronic Myeloid Leukaemia: an Evaluation of the Tyrosine Kinase Inhibitors Axitinib and Asciminib H
    Lindström and Friedman BMC Cancer (2020) 20:397 https://doi.org/10.1186/s12885-020-06782-9 RESEARCH ARTICLE Open Access The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib H. Jonathan G. Lindström and Ran Friedman* Abstract Background: Chronic myeloid leukaemia is in principle a treatable malignancy but drug resistance is lowering survival. Recent drug discoveries have opened up new options for drug combinations, which is a concept used in other areas for preventing drug resistance. Two of these are (I) Axitinib, which inhibits the T315I mutation of BCR-ABL1, a main source of drug resistance, and (II) Asciminib, which has been developed as an allosteric BCR-ABL1 inhibitor, targeting an entirely different binding site, and as such does not compete for binding with other drugs. These drugs offer new treatment options. Methods: We measured the proliferation of KCL-22 cells exposed to imatinib–dasatinib, imatinib–asciminib and dasatinib–asciminib combinations and calculated combination index graphs for each case. Moreover, using the median–effect equation we calculated how much axitinib can reduce the growth advantage of T315I mutant clones in combination with available drugs. In addition, we calculated how much the total drug burden could be reduced by combinations using asciminib and other drugs, and evaluated which mutations such combinations might be sensitive to. Results: Asciminib had synergistic interactions with imatinib or dasatinib in KCL-22 cells at high degrees of inhibition. Interestingly, some antagonism between asciminib and the other drugs was present at lower degrees on inhibition.
    [Show full text]
  • Combinatorial Efficacy of Entospletinib and Chemotherapy in Patient-Derived Xenograft Models of Infant Acute Lymphoblastic Leukemia
    Acute Lymphoblastic Leukemia SUPPLEMENTARY APPENDIX Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia Joseph P. Loftus, 1* Anella Yahiaoui, 2* Patrick A Brown, 3 Lisa M. Niswander, 1 Asen Bagashev, 1 Min Wang, 2 Allyson Shauf, 2 Stacey Tannheimer 2 and Sarah K. Tasian 1,4 1Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, Philadelphia, PA; 2Gilead Sci - ences, Foster City, CA; 3Department of Pediatrics, Division of Pediatric Hematology/Oncology, Johns Hopkins University and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD and 4Department of Pediatrics and Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA *JPL and AY contributed equally as co-first authors. ©2021 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2019.241729 Received: October 28, 2019. Accepted: May 8, 2020. Pre-published: May 15, 2020. Correspondence: SARAH K. TASIAN - [email protected] SUPPLEMENTAL DATA SUPPLEMENTAL METHODS Cell Titer Glo viability assays The human B-acute lymphoblastic leukemia (B-ALL) cell lines NALM-6 (non-KMT2A- rearranged) and HB11;19, KOPN-8, and HB11;19 (all KMT2A-rearranged) were obtained from the German Collection of Microorganisms and Cell Cultures GmbH (Deutsche Sammlung von Mikroorganismen und Zellkulturen; DSMZ), validated by short tandem repeat identity testing, and confirmed to be Mycoplasma-free. ALL cells were incubated in vitro with dimethyl sulfoxide or increasing concentrations of entospletinib (Gilead Sciences), fostamatinib (Selleckchem), dasatinib (LC Labs), selumetinib (LC Labs), and/or dexamethasone as indicated in Supplemental Figure 1 for 72 hours, then assessed for cell viability via Cell Titer Glo luminescent assays (Promega) according to manufacturer’s instructions using an IVIS Spectrum bioluminescent imaging instrument and Living Image software (PerkinElmer) (1, 2).
    [Show full text]
  • Antibody–Drug Conjugates: the Last Decade
    pharmaceuticals Review Antibody–Drug Conjugates: The Last Decade Nicolas Joubert 1,* , Alain Beck 2 , Charles Dumontet 3,4 and Caroline Denevault-Sabourin 1 1 GICC EA7501, Equipe IMT, Université de Tours, UFR des Sciences Pharmaceutiques, 31 Avenue Monge, 37200 Tours, France; [email protected] 2 Institut de Recherche Pierre Fabre, Centre d’Immunologie Pierre Fabre, 5 Avenue Napoléon III, 74160 Saint Julien en Genevois, France; [email protected] 3 Cancer Research Center of Lyon (CRCL), INSERM, 1052/CNRS 5286/UCBL, 69000 Lyon, France; [email protected] 4 Hospices Civils de Lyon, 69000 Lyon, France * Correspondence: [email protected] Received: 17 August 2020; Accepted: 10 September 2020; Published: 14 September 2020 Abstract: An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years. While in 2009 only gemtuzumab ozogamicin (Mylotarg®) was used clinically, in 2020, 9 Food and Drug Administration (FDA)-approved ADCs are available, and more than 80 others are in active clinical studies. This review will focus on FDA-approved and late-stage ADCs, their limitations including their toxicity and associated resistance mechanisms, as well as new emerging strategies to address these issues and attempt to widen their therapeutic window. Finally, we will discuss their combination with conventional chemotherapy or checkpoint inhibitors, and their design for applications beyond oncology, to make ADCs the magic bullet that Paul Ehrlich dreamed of. Keywords: antibody–drug conjugate; ADC; bioconjugation; linker; payload; cancer; resistance; combination therapies 1.
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, A
    Cancer Therapy: Preclinical Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, aHeatShockProtein90Inhibitor,againstGastrointestinal Stromal Tumor ^ Associated PDGFRAD842V Mutation Barbara Dewaele,1BartoszWasag,1Jan Cools,1,4 Raf Sciot,2 Hans Prenen,3 PeterVandenberghe,1 AgnieszkaWozniak,3 Patrick Scho« ffski,3 Peter Marynen,1,4 and Maria Debiec-Rychter1 Abstract Purpose: Activating mutations in platelet-derived growthfactor receptor- a (PDGFRA) have been reported in f5% to 10% of patients withgastrointestinal stromal tumors (GIST). Imatinib efficiently inhibits the juxtamembrane PDGFRA mutations, whereas many tyrosine kinase domain activation loop PDGFRA mutations confer primary resistance to imatinib. In this study, we compared the efficacy of second-line tyrosine kinase inhibitors such as dasatinib, sorafenib, and nilotinib against two GIST-related PDGFRA mutants, PDGFRAD842V and PDGFRADDIM842-844. In addition, we sought to investigate the inhibitory effect of the heat shock protein 90 inhibitor, IPI-504, on these mutants. Experimental Design: Primary imatinib-resistant tumor cells and cell lines expressing imatinib- resistant PDGFRAD842V or imatinib-sensitive PDGFRADDIM842-844 mutants were treated with different concentrations of dasatinib, sorafenib, nilotinib, and IPI-504. The effect of treatment on proliferation, survival, and signaling was determined. Results: All inhibitors tested exhibited a high efficacy toward the PDGFRADDIM842-844 mutant. In contrast, ex vivo and in vitro assays revealed that only dasatinib potently inhibited the D842V PDGFRA isoform withan IC 50 value of 62 nmol/L. Sorafenib and nilotinib were significantly less efficacious against this mutation, inhibiting the PDGFRA kinase activity at >1, 0 0 0 a nd >5,000 nmol/L, and suppressing the proliferation of the cells expressing the PDGFRAD842V mutant withan IC 50 value of 239 and 1,310 nmol/L, respectively.
    [Show full text]
  • Hypopigmentation of the Skin and Hair Associated with Targetedclinical Therapies and BIOMEDICAL INVESTIGATION
    M.T.J. Vega González, et al.: Hypopigmentation of the Skin and Hair Associated with TargetedCLINICAL Therapies AND BIOMEDICAL INVESTIGATION. 2014;1 REVIEW ARTICLE Journal of Cancerology. 2014;1:67-72 Hypopigmentation of the Skin and Hair Associated with Targeted Therapies MARÍA TERESA DE JESÚS VEGA GONZÁLEZ1, JORGE LUIS MARTÍNEZ TLAHUEL2 AND ELENA CINTHLELY MARTÍNEZ GUERRA3 1Skin and Soft Tissue Unit; 2Department of Medical Oncology. National Cancer Institute, Mexico City, Mexico; 3Dr. Ladislao de la Pascua Dermatology Center, Department of Health, Mexico City, Mexico © Permanyer Publications 2014 ABSTRACT In the last two decades the US Food and Drug Administration has granted approval for multiple molecules for use in the treatment of cancer. These targeted therapies, aimed at inhibiting specific molecules, cause numerous adverse effects at the skin, for example, acneform dermatitis, mucosal, hair and nail alterations, and depigmentation of skin and hair, which have been seldom described in the literature. In this article we will focus on the side effects of tyrosine kinase inhibitors in particular and try to show how these drugs affect melanogenesis in hair follicles, triggering changes in skin and hair pigmentation. (J CANCEROL. 2014;1:67-72) Corresponding author: Elena Cinthlely Martínez Guerra, [email protected] Key words: Depigmentation. Targeted therapy. Tyrosine kinase inhibitor. Correspondence to: Elena Cinthlely Martínez Guerra Dr. Vértiz, 464. Esq. Eje 3 Sur Col. Buenos Aires, Del. Cuauhtémoc 06780 México, D.F., México Received for publication: 31-10-2014 E-mail: [email protected] Accepted for publication: 18-11-2014 of the publisher. No part of this publication may be reproduced or photocopying without the prior written permission 67 Journal of Cancerology.
    [Show full text]
  • The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer Thomas C
    Published OnlineFirst May 24, 2016; DOI: 10.1158/1535-7163.MCT-15-0702 Cancer Biology and Signal Transduction Molecular Cancer Therapeutics The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer Thomas C. Beadnell1, Katie M. Mishall1, Qiong Zhou1, Stephen M. Riffert1, Kelsey E. Wuensch1, Brittelle E. Kessler1, Maia L. Corpuz1, Xia Jing1, Jihye Kim2, Guoliang Wang2, Aik Choon Tan2,3, and Rebecca E. Schweppe1,3 Abstract Advanced stages of papillary and anaplastic thyroid cancer resistant cell lines. Interestingly, activation of the MAPK path- represent a highly aggressive subset, in which there are currently way was increased in all four of the dasatinib-resistant cell lines, few effective therapies. We and others have recently demon- likely due to B-Raf and c-Raf dimerization. Furthermore, strated that c-SRC is a key mediator of growth, invasion, and MAP2K1/MAP2K2 (MEK1/2) inhibition restored sensitivity in metastasis, and therefore represents a promising therapeutic all four of the dasatinib-resistant cell lines, and overcame target in thyroid cancer. However, clinically, Src inhibitor acquired resistance to dasatinib in the RAS-mutant Cal62 cell efficacy has been limited, and therefore further insights are line, in vivo. Together, these studies demonstrate that acquisi- needed to define resistance mechanisms and determine rational tion of the c-SRC gatekeeper mutation and MAPK pathway combination therapies. We have generated four thyroid cancer signaling play important roles in promoting resistance to the cell lines with a greater than 30-fold increase in acquired Src inhibitor dasatinib. We further demonstrate that up-front resistance to the Src inhibitor dasatinib.
    [Show full text]
  • Revisiting Clinical Trials Using EGFR Inhibitor-Based
    www.impactjournals.com/oncotarget/ Oncotarget, May, Vol.4, No 5 Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population Jennifer Wheler1, Gerald Falchook1, Apostolia M. Tsimberidou1, David Hong1, Aung Naing1, Sarina Piha-Paul1, Su S. Chen2, John Heymach3, Siqing Fu1, Bettzy Stephen1, Jansina Y. Fok1, Filip Janku1, Razelle Kurzrock4 1 Department of Investigational Cancer Therapeutics – a Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Texas 2 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Texas 3 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas 4 Moores Cancer Center, University of California, San Diego Correspondence to: Jennifer Wheler, email: [email protected] Keywords: EGFR mutation, EGFR wild-type, non-small cell lung cancer, phase I trials, resistance, squamous cell Received: May 10, 2013 Accepted: June 2, 2013 Published: June 4, 2013 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT: Purpose: Single-agent EGFR inhibitor therapy is effective mainly in patients with lung cancer and EGFR mutations. Treating patients who develop resistance, or who are insensitive from the outset, often because of resistant mutations, other aberrations or the lack of an EGFR mutation, probably requires rational combinations. We therefore investigated the outcome of EGFR inhibitor-based combination regimens in patients with heavily-pretreated non-small cell lung cancer (NSCLC) referred to a Phase I Clinic.
    [Show full text]
  • A Network Medicine Approach for Drug Repurposing in Duchenne Muscular Dystrophy
    G C A T T A C G G C A T genes Article A Network Medicine Approach for Drug Repurposing in Duchenne Muscular Dystrophy Salvo Danilo Lombardo 1 , Maria Sofia Basile 2 , Rosella Ciurleo 2, Alessia Bramanti 2, Antonio Arcidiacono 3, Katia Mangano 3 , Placido Bramanti 2, Ferdinando Nicoletti 3,* and Paolo Fagone 3 1 Department of Structural & Computational Biology at the Max Perutz Labs, University of Vienna, 1010 Vienna, Austria; [email protected] 2 IRCCS Centro Neurolesi “Bonino-Pulejo”, Via Provinciale Palermo, Contrada Casazza, 98124 Messina, Italy; sofi[email protected] (M.S.B.); [email protected] (R.C.); [email protected] (A.B.); [email protected] (P.B.) 3 Department of Biomedical and Biotechnological Sciences, University of Catania, Via S. Sofia 89, 95123 Catania, Italy; [email protected] (A.A.); [email protected] (K.M.); [email protected] (P.F.) * Correspondence: [email protected] Abstract: Duchenne muscular dystrophy (DMD) is a progressive hereditary muscular disease caused by a lack of dystrophin, leading to membrane instability, cell damage, and inflammatory response. However, gene-editing alone is not enough to restore the healthy phenotype and additional treat- ments are required. In the present study, we have first conducted a meta-analysis of three microarray datasets, GSE38417, GSE3307, and GSE6011, to identify the differentially expressed genes (DEGs) be- tween healthy donors and DMD patients. We have then integrated this analysis with the knowledge Citation: Lombardo, S.D.; Basile, obtained from DisGeNET and DIAMOnD, a well-known algorithm for drug–gene association discov- M.S.; Ciurleo, R.; Bramanti, A.; eries in the human interactome.
    [Show full text]
  • Ado-Trastuzumab Emtansine: Drug Information
    Official reprint from UpToDate® www.uptodate.com ©2017 UpToDate® Ado-trastuzumab emtansine: Drug information Copyright 1978-2017 Lexicomp, Inc. All rights reserved. (For additional information see "Ado-trastuzumab emtansine: Patient drug information ") For abbreviations and symbols that may be used in Lexicomp (show table) ALERT: US Boxed Warning Do not interchange: Do not substitute ado-trastuzumab emtansine (Kadcyla) for or with trastuzumab (Herceptin). Hepatotoxicity: Serious hepatotoxicity has been reported, including liver failure and death. Monitor serum transaminases and bilirubin prior to initiation of treatment and prior to each dose. Reduce the dose or discontinue ado- trastuzumab emtansine as appropriate in cases of increased serum transaminases or total bilirubin. Cardiotoxicity: Ado-trastuzumab emtansine administration may lead to reductions in left ventricular ejection fraction (LVEF). Evaluate left ventricular function in all patients prior to and during treatment. Withhold treatment for a clinically significant decrease in left ventricular function. Pregnancy: Exposure to ado-trastuzumab emtansine during pregnancy can result in embryo-fetal harm. Advise patients of these risks and the need for effective contraception. Brand Names: US Kadcyla Brand Names: Canada Kadcyla Pharmacologic Category Antineoplastic Agent, Anti-HER2; Antineoplastic Agent, Antibody Drug Conjugate; Antineoplastic Agent, Antimicrotubular; Antineoplastic Agent, Monoclonal Antibody Dosing: Adult Note: Do not substitute ado-trastuzumab emtansine (US) or trastuzumab emtansine (Canada) for or with conventional trastuzumab; products are different and are NOT interchangeable. Breast cancer, metastatic, HER2+: IV: 3.6 mg/kg every 3 weeks until disease progression or unacceptable toxicity; Maximum dose: 3.6 mg/kg Missed or delayed doses: If a planned dose is missed or delayed, administer as soon as possible (at the dose and rate most recently tolerated), do not wait until the next planned cycle.
    [Show full text]
  • Targeted Therapy–Based Combination Treatment in Rhabdomyosarcoma Anke E.M
    Review Molecular Cancer Therapeutics Targeted Therapy–based Combination Treatment in Rhabdomyosarcoma Anke E.M. van Erp1, Yvonne M.H. Versleijen-Jonkers1, Winette T.A. van der Graaf1,2, and Emmy D.G. Fleuren3 Abstract Targeted therapies have revolutionized cancer treatment; in this regard, as this affects multiple hallmarks of cancer at however, progress lags behind in alveolar (ARMS) and embry- once. To determine the most promising and clinically relevant onal rhabdomyosarcoma (ERMS), a soft-tissue sarcoma mainly targeted therapy–based combination treatments for ARMS and occurring at pediatric and young adult age. Insulin-like growth ERMS, we provide an extensive overview of preclinical and factor 1 receptor (IGF1R)-directed targeted therapy is one of the (early) clinical data concerning a variety of targeted therapy– few single-agent treatments with clinical activity in these dis- based combination treatments. We concentrated on the most eases. However, clinical effects only occur in a small subset of common classes of targeted therapies investigated in rhabdo- patients and are often of short duration due to treatment myosarcoma to date, including those directed against receptor resistance. Rational selection of combination treatments of tyrosine kinases and associated downstream signaling path- either multiple targeted therapies or targeted therapies with ways, the Hedgehog signaling pathway, apoptosis pathway, chemotherapy could hypothetically circumvent treatment resis- DNA damage response, cell-cycle regulators, oncogenic fusion tance mechanisms and enhance clinical efficacy. Simultaneous proteins, and epigenetic modifiers. Mol Cancer Ther; 17(7); 1365–80. targeting of distinct mechanisms might be of particular interest Ó2018 AACR. Introduction treatment including surgery, chemotherapy, and radiotherapy has increased the 5-year overall survival (OS) to approximately Rhabdomyosarcoma is the most common type of soft-tissue 70%–90% for intermediate- and low-risk rhabdomyosarcoma, sarcoma (STS) observed in young patients with the most respectively.
    [Show full text]